{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.23","value":"-2.47"},{"groupId":"OG001","spread":"1.28","value":"-2.16"},{"groupId":"OG002","spread":"1.12","value":"-2.68"}]}],"title":"Week 76 (n=107, 61, 31)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.16","value":"-2.56"},{"groupId":"OG001","spread":"1.23","value":"-2.02"},{"groupId":"OG002","spread":"1.40","value":"-2.35"}]}],"title":"Week 128 (n=79, 47, 18)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"31"}],"units":"Participants"}],"description":"Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (patient's global VAS). DAS28-CRP=0.56\\*square root (sqrt)(TJC28)+0.28\\*sqrt(SJC28)+0.36\\*natural log(CRP+1)+0.014\\*patient's global VAS+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP \\<2.6. A decrease in DAS28-CRP indicated an improvement in participant's condition.","dispersionType":"Standard Deviation","groups":[{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"4 mg LY3009104 QD - Parts C and D"},{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.\n\nDose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"},{"description":"Received 8 mg LY3009104 QD in Parts A, B and C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"}],"paramType":"MEAN","populationDescription":"All participants who received study drug in Parts C and D and had DAS28-CRP evaluated at analysis time points. LOCF was used to impute missing post-baseline values.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 76 and 128","title":"Mean Change From Baseline to Weeks 76 and 128 in DAS28-CRP","type":"SECONDARY","unitOfMeasure":"units on a scale"}